Commonwealth Numbered Regulations

1986 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 5

                                   SCHEDULE 5                      Regulation
7
AMENDMENTS OF SCHEDULE 5 TO THE
NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1. Omit item 11. 2. Omit
item 14. 3. Omit item 29. 4. Omit item 40, substitute the following item:
      "40 Cholestyramine                Bile salt malabsorption

Hypercholesterolaemia
Pruritus associated with partial biliary
obstruction not responding to other
therapy
Severe diarrhoea associated with
pelvic irradiation". 5. Omit item 42, substitute the following item:
      "42 Cimetidine                    With the written authority of the

Secretary -
Duodenal ulcer (including pyloric
ulcer), confirmed by X-ray,
endoscopy or surgery
Gastric ulcer, initial, confirmed by
X-ray, endoscopy or surgery
Gastric ulcer, recurrent (benign
gastric ulcer recurring within 12
months of commencing initial
therapy), confirmed by X-ray,
endoscopy or surgery
Oesophageal stricture, recurrent,
due to proven chronic ulcer
occurring within gastric
epithelium where dilatation has
been required
Severe ulcerating (erosive)
oesophagitis, confirmed by
endoscopy
Ulcerating (erosive) oesophagitis in
scleroderma
Zollinger-Ellison syndrome, proven
by investigation". 6. Omit item 45, substitute the following item:
      "45 Clomiphene Tablets, B.P.      Anovulatory infertility

Patients undergoing in-vitro
fertilisation". 7. Omit item 47. 8. After item 49 insert the following item:

"49A Cyproheptadine Tablets, B.P. Prevention of migraine". 9. Omit item 57.
10. Omit item 65. 11. Omit item 72, substitute the following item:
      "72 Etretinate                    With the written authority of the

Secretary -
Treatment initiated in a hospital
(in-patient or out-patient) of -
Darier's disease
Erythrokeratoderma
Pityriasis rubra pilaris
Severe congenital ichthyosis
(lamellar, bullous and
sexlinked)
Severe intractable psoriasis
Severe palmo-plantar
keratoderma
For the continuing treatment of a
patient who has already received,
for more than 6 months, therapy
with etretinate for a condition
listed above". 12. Omit item 74. 13. Omit item 82. 14. Omit item 91,
substitute the following item:
      "91 (1) Insulin Isophane, Human   Diabetics exhibiting lipoatrophy,

                (Synthetic)               lipohypertrophy, local allergy or

          (2) Insulin Isophane, Human     immunologic resistance

(Synthetic) and Insulin Newly diagnosed insulin dependent
                Neutral, Human            diabetics".

(Synthetic)

(3) Insulin Neutral, Human
(Synthetic)

(4) Insulin Zinc Suspension,
Human (Synthetic)

(5) Insulin Zinc Suspension
(Crystalline), Human
(Synthetic) 15. After item 106 insert the following item:

"106A Methdilazine Hydrochloride Prevention of migraine". 16. Omit item 127.
17. Omit item 150, substitute the following item:
      "150 Ranitidine Hydrochloride     With the written authority of the

Secretary -
Duodenal ulcer (including pyloric
ulcer), confirmed by
X-ray, endoscopy or surgery
Gastric ulcer, initial, confirmed by
X-ray, endoscopy or surgery
Gastric ulcer, recurrent (benign
gastric ulcer recurring within 12
months of commencing initial
therapy), confirmed by X-ray,
endoscopy or surgery
Oesophageal stricture, recurrent,
due to proven chronic ulcer
occurring within gastric
epithelium where dilatation has
been required
Severe ulcerating (erosive)
oesophagitis, confirmed by
endoscopy
Ulcerating (erosive) oesophagitis in
scleroderma
Zollinger-Ellison syndrome, proven
by investigation". 18. After item 151 insert the following items:
      "151A Silver Sulphadiazine,       For prevention and treatment of

Cream,
        1%, 100 g                         infection in partial or full skin

thickness loss due to burns
Stasis ulcers
151B Silver Sulphadiazine, Cream, With the written authority of the
        1%, 500 g                         Secretary -

Treatment, in a hospital, of burns". 19. Omit item 152, substitute the
following items:
      "152 Silver Sulphadiazine with    For prevention and treatment of

        Chlor-hexidine Gluconate Cream,   infection in partial or full skin

        1%-0.2%, 100 g                    thickness loss due to burns

Stasis ulcers
      152A Silver Sulphadiazine with    With the written authority of the

        Chlor-hexidine Gluconate Cream,   Secretary -

        1%-0.2%, 500 g                    Treatment, in a hospital, of
burns". 20. After item 158 insert the following item:
      "158A Sterculia, B.P., with       Any disease or condition in a

        Frangula Bark, B.P.               paraplegic or quadriplegic patient

For use by patients who are receiving
long-term extensive nursing care in
hospitals or nursing homes
For use by patients for whose care a
Commonwealth Domiciliary
Nursing Care Benefit is approved". 21. Omit item 159. 22. Omit item 160. 23.
Omit item 171, substitute the following item:
      "171 Ticarcillin Sodium           Infections where positive

bacteriological evidence confirms
that ticarcillin sodium is an
appropriate therapeutic agent
Septicaemia, suspected or proven". 24. Omit item 180. 44p